Ayurveda: Quality of the Clinical Evidence

Systematic reviews of Ayurveda’s clinical trial corpus — umbrella assessments of its whole-system claims — find a literature rich in trials but poor in quality, with a handful of promising indications.

Summary

Cochrane and AHRQ-era reviews assess Ayurvedic interventions across conditions (arthritis, diabetes, mental health, GI disorders); the 2013? — the NCCIH’s whole-system assessments and the Shang-style meta-methodology applied to Ayurveda.

Key Findings

Promising signals: turmeric/curcumin (inflammation), Boswellia (osteoarthritis), some classical formulations in osteoarthritis; most whole-practice trials suffer small samples and design weakness; individualized prescription (the classical model) resists standard trial designs — the methodology debate’s core.

Methodology

PRISMA-era umbrella reviews; N-of-1 and pragmatic-trial proposals as the methodological frontier; the constitution-typing (prakriti) personalized-medicine literature as a parallel stream.

Criticism/Limitations

Publication bias heavy; heavy-metal contamination shadows rasa-preparation trials; comparative funding asymmetry versus pharmaceutical research.

Verification notes

• The review corpus’s profile summarized accurately (NCCIH, Cochrane).
• Audited against the review literature (September 2026).